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Purpose: This study retrospectively evaluated the technical and hemostatic outcomes of reconstructive and deconstructive
endovascular management in patients with head and neck cancers associated with carotid blowout syndrome (CBS).
Methods:Twenty-four patients with head and neck cancers with CBS involving the main trunk of carotid artery underwent
endovascular therapy. This included reconstructive management with self-expandable stent grafts to preserve the diseased
carotid artery in 11 patients and deconstructive management with balloons, coils, or acrylic adhesives to occlude the
diseased carotid artery in 13 patients. Based on clinical severity and therapeutic priority, we classified CBS in our patients
into two groups: acute or impending and threatened. The angiographic severity was graded from 0 to 3. Evaluation of
technical outcome included technical success, initial and delayed complications, and patency of stent graft in the
reconstructive group. The hemostatic outcome was evaluated by immediate hemostatic result, rebleeding, and duration
of hemostasis. Sex, age, clinical and angiographic severities, local wound complications, and location of the pathologic
lesion were examined as predictors of the technical and hemostatic outcomes of endovascular management by using Cox
regression method.
Results: Technical success and immediate hemostasis were achieved in all patients of both groups. Initial complications
during the procedures were encountered in four patients (36.4%) who underwent reconstructive management and in one
patient (7.7%) who underwent deconstructive management (P .142). Delayed complications during the follow-up were
seen in one patient (9.1%) with reconstructive management and one patient (7.7%) with deconstructive management (P>
.99). Rebleeding occurred in five patients (45.5%) in the reconstructive management group and in three patients (23.1%)
in the deconstructive management group (P  .659). The mean duration of hemostasis after initial reconstructive and
deconstructive management was 4.0  8.1 and 8.5  10.1 months, respectively (P  .249). Rebleeding was noted in 7
of 11 patients (63.6%) with acute CBS and in 1 of 13 patients (7.7%) with impending and threatened CBS (P  .008).
Conclusion: There is no significant difference in technical and hemostatic outcomes between the reconstructive and
deconstructive endovascular management methods. Hemostatic results were influenced by clinical severity. The rebleed-
ing rate is higher in patients with advanced and acute clinical severity. ( J Vasc Surg 2008;47:936-45.)Carotid blowout, or rupture of the carotid artery (CA),
is a life-threatening complication associated with head and
neck cancer and its therapy.1,2 The reported incidence of
CA rupture after radical neck dissection is 4.3%.3 Patients
with carotid blowout syndrome (CBS) can have a variety of
clinical presentations due to rupture of the CA, including
acute hemorrhage or exposure of part of the CA.4-6 Carotid
blowout syndrome tends to occur in patients with head and
neck cancers and those with radiation-induced necrosis,
recurrent tumors, wound complications, or pharyngocuta-
neous fistulas.1-4
Emergency surgical management of CBS is often tech-
nically difficult to perform in previously irradiated areas and
is associated with high neurologic morbidity and mortality
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936rates. The reported average neurologic morbidity and mor-
tality rates associated with surgical management of CBS are
40% and 60%, respectively.7 Deconstructive endovascular
therapy, such as with permanent balloon occlusion of the
diseased carotid artery, has improved outcomes1,6,7; how-
ever, as many as 15% to 20% of patients with CBS who are
treated with permanent carotid occlusion experience im-
mediate or delayed cerebral ischemia.1,8 A balloon occlu-
sion test may be performed before threatened CBS is
treated definitively, but this test is usually not possible in
acute cases. In addition, test occlusion or even positron
emission tomography studies may not help in identifying
the small subset of patients in whom delayed hemodynamic
ischemia develops after the carotid artery is permanently
occluded.1,4,7-9 These results highlight the limitations of
deconstructive endovascular therapy for patients with CBS.
Stent grafting has the potential to preserve the diseased
CA and achieve hemostasis. Some authors report it as prom-
ising in treating CBS in patients at risk of CA occlusion8,10;
however, some studies have described unfavorable long-term
outcomes.5,11-13 Therefore, the purpose of this study was to
compare the technical and hemostatic outcomes of endovas-
cular reconstruction using self-expandable stent grafts with
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or acrylic adhesive in the management of CBS in patients
with head and neck cancers. We also provide an assessment
of the clinical severity in our patients compared with their
angiographic findings to highlight the importance of early
diagnosis and management of CBS.
MATERIALS AND METHODS
Patient population. This retrospective study was ex-
empt from Institutional Review Board approval. Written
consent was obtained from each patient or the family before
intervention. From 2003 to 2006, 1632 patients with head
and neck cancers were treated in our institute, and 56
patients sustained CBS. Two patients could not accept
either surgical or endovascular management due to profuse
hemorrhage with hypovolemic shock. Two patients were
treated with surgical ligation.
The study excluded 28 patients because their patho-
logic lesions involved the branches of external carotid artery
(ECA) that were only eligible for deconstructve manage-
ment. The study included 24 patients with CBS involving
the main trunk of the CA (Table I). We included these
patients because the locations of their pathologic lesions
could be treated by either reconstructive or deconstructive
endovascular therapy. Eleven men with a mean age of 49.2
7.8 years (range, 35-65 years) underwent reconstructive
Table I. Baseline characteristics of patients with reconstru
Variable Reconstructive (n
Sex, No (%)
Male 11 (100)
Female 0 (0)
Age, mean  SD (range) years 49.2  7.8 (35
Clinical cancer diagnosis, No.
Nasopharyngeal 1
Hypopharyngeal 5
Laryngeal 2
Tongue 1
Buccal
Sinus
Parotid gland 1
Tonsil 1
Local complications, No.
Fistular formationa 5
Wound complicationsb 10
CBS group, No (%)
Acute 5 (45.5)
Impending and threatened 6 (54.5)
Angiographic grade, No (%)
0 and 1 3 (27.3)
2 and 3 8 (72.7)
Location of lesion (n  28) 13
ICA, No (%) 2 (15.5)
CAB, No (%) 5 (38.4)
CCA, No (%) 6 (46.1)
ECA, No (%) 0 (0)
CAB, Carotid artery bifurcation; CBS, carotid blowout syndrome; CCA, co
aPharyngocutaneous or aerodigestive.
bNecrosis, ulceration, sinus tract.endovascular surgery in which self-expandable stent graftswere placed to preserve the diseased CA. Thirteen patients
(10men and 3 women) with amean age of 51.4 9.9 years
(range, 34-67 years) underwent deconstructive endovascu-
lar surgery in which the permanent CA occlusion was done.
All patients had received radiation therapy or chemoradio-
therapy and presented with various degrees of irradiation-
induced change in their head and neck regions. Previous
surgical therapy for the malignancy had been done in 8 of
the 11 patients in reconstructive group and 10 of the 13
patients in the deconstructive group.
Clinical severity was used to classify CBS into three
types: acute, impending, and threatened1,7:
● Acute CBS was defined as profuse hemorrhage that
was not controlled with surgical packing, with the
vessel being completely ruptured, and the patient’s
condition deteriorating rapidly if immediate resuscita-
tion and stabilization had not been accomplished be-
fore definite treatment.
● Impending CBS was defined as short episodes of sen-
tinel hemorrhage that resolved spontaneously or with
simple surgical packing; however, complete rupture
was a certainty.
● Threatened CBS was defined as exposure of the CA
because of wound breakdown or neoplastic invasion of
the carotid system; and although the hemorrhage had
and deconstructive endovascular management
) Deconstructive (n  13) P
10 (76.9) .223
3 (23.1)
51.4  9.9 (34-67) .557
3 .596
1 .061
1 .576
1 1
3 .223
2 .482
2 1
.458
6 .973
11 1
6 (46.1) .973
7 (53.9)
5 (38.5) .769
8 (61.5)
15
7 (46.7) .115
3 (20) .410
2 (13.3) .096
3 (20) .226
n carotid artery; ECA, external carotid artery; ICA, internal carotid artery.ctive
 11
-65)
mmonot yet occurred, rupture was almost inevitable if the
JOURNAL OF VASCULAR SURGERY
May 2008938 Chang et alexposed vessel was not promptly covered with healthy
vascularized tissue.
Based on therapeutic priority, we further classified CBS
in our patients into two groups: (1) acute and (2) impend-
ing and threatened. The patients of the former group had a
clinical emergency that required emergency treatment. The
latter group was composed of patients whose status could
be treated more electively.
Locations of pathologic vascular lesions, such as
pseudoaneurysms, were recorded as the internal carotid
artery (ICA), carotid bifurcation (CBF), ECA, or common
carotid artery (CCA). The ECA was designated the main
trunk of ECA proximal to the orifice of linguofacial trunk.
If endovascular management was anticipated, a balloon
test occlusion was attempted if the patient was hemody-
namically stable and not bleeding profusely. A standardized
protocol has been described in detail in the literature.1,7
The indications for reconstructive endovascular therapy
were the patients at risk of permanent carotid occlusion,
such as incomplete circle of Willis on angiograms (patients
3 and 4), contralateral carotid severe stenosis or total
occlusion, intolerance to a balloon occlusion test (patients
8, 10, and 11), or emergency status of the patient preclud-
ing an occlusion test (patients 1, 2, 5-7, and 9).7,9 The
deconstructive method was done for patients without the
above risks of carotid occlusion (patients 1-5, 7, and 10-12)
or for those refused reconstructive management (patients
6, 8, 9, and 13).
Angiographic evaluation. We used a transfemoral ar-
terial approach to obtain a complete neuroangiogram of
the supra-aortic arteries and their branches. The angio-
graphic findings were used to classify the severity of vascular
injury as grades 0 to 3.14 A grade of 0 meant no angio-
graphic vascular disruption. Grade 1 was defined as focal
irregularity or slight focal bulging of the diseased CA, such
as a focal weakening in the vascular wall. Grade 2 was
defined as a pseudoaneurysm of the injured CA, in which
there was a focal CA rupture confined by the integrity of the
surrounding tissue. Grade 3 was defined as active extrava-
sation from the completely ruptured CA. We further clas-
sified grades 0 and 1 as slight carotid injury and grades 2
and 3 as advanced carotid disruption. The former group
had a complete or weakening vascular wall. The latter
group had an incomplete or ruptured vascular wall. We
compared these angiographic findings with the clinical
severities and patient outcomes.
Medication for reconstructive management. Patients
with threatened CBS were premedicated with a dual anti-
platelet regimen consisting of orally administered aspirin
(324 mg) and clopidogrel (300 mg) 1 day before treat-
ment. Patients with acute or impending CBS were prophy-
lactically given intravenous glycoprotein IIb/IIIa receptor
inhibitor (Aggrastat; Merck & Co, Inc, West Point, Pa)
during the interventional procedure.11 We gave an initial
intravenous infusion at 0.4 g/kg/min for 15 to 20 min-
utes, followed by continuous infusion at 0.1 g/kg/min
for 4 to 6 hours after the procedure. Approximately 50 to70 U/Kg of heparin was also given to keep the activated
clotting time 250 seconds.
After deployment of the self-expandable stent graft, a
dual antiplatelet regimen with aspirin (324 mg) and clopi-
dogrel (75 mg) was begun. One month later, this regimen
was changed to aspirin (100 mg) for life-long use. Because
patient 4 sustained a brain abscesses after the stent graft
deployment, we gave 4-week prophylactic antibiotic ther-
apy to patients 7 through 11.
Reconstructive management. After identifying the
pathologic lesions, we exchanged the diagnostic catheter
and wire to a 10F or 11F introducer sheath and a .0.35-
inch, 300-cm Amplatz exchange wire (Cook, Blooming-
ton, Ind) through the right femoral artery into the cervical
ICA. A self-expandable Wallgraft stent graft (Boston Sci-
entific Corp, Natick, Mass) was then advanced along this
exchange wire to the CA, where it was appropriately de-
ployed11 (Fig 1). To avoid rebleeding from reconstitution
through the branches of ECA, we placed fiber coils in the
main trunk of the ECA before deployment of stent grafts if
the pathologic lesions were close to the CBF. A control
angiogram was obtained immediately and 15 minutes after
deployment of the stent graft to confirm appropriate posi-
tioning of the stent graft and patency of the CA.11 The
reconstructive endovascular management was considered
complete when adequate coverage of the pathologic lesion
by stent graft was achieved or clinical hemostasis was
reached, or both.
Deconstructive management. A 7F Shuttle sheath
(Cook, Minneapolis, Minn) was placed through the femo-
ral artery to the diseased CCA. Two types of deconstructive
management were used in this study: cross occlusion and
proximal occlusion. Cross occlusion consisted of deploy-
ment of embolic materials from the pathologic lesion or
from the CA distal to the pathologic lesion to its proximal
site (Fig 2). In such situations, we advanced twomicrocath-
eters into the CA.One “distal microcatheter” was advanced
to the CA of the pathologic lesion or distal to it, and the
other “proximal microcatheter,” mounted with a detach-
able balloon, was placed in the CA proximal to the lesion.
We inflated and deployed the detachable balloon from
the proximal microcatheter first. We then deployed micro-
coils (Target Therapeutics, Fremont, Calif), injected acrylic
adhesive (Histoacryl, Braun, Germany), or deployed a pre-
mounted balloon through the distal microcatheter to oc-
clude the pathologic lesion and its adjacent CA. Proximal
occlusion consisted of placing the embolic materials in the
CA proximal to the pathological lesions. At least two de-
tachable balloons were serially inflated and deployed to
ensure permanent vascular occlusion.1 Proximal occlusion
was used in cases when associated focal carotid stenosis or
tortuosity impeded the balloon or microcatheter position-
ing to cross the lesions. Successful deconstructive manage-
ment was defined as complete obliteration of the patho-
logic lesion and the related CA and the achievement of
clinical hemostasis.
Outcome evaluation. Immediate postprocedural out-
comes were evaluated by the interventional neuroradiolo-
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technical outcomes included technical success, initial and
delayed complications, and patency of the stent grafts of the
reconstructive group. The complications presented during
the therapeutic procedures were defined as “initial,” and
those presented after the procedures were defined as “de-
layed.” Hemostatic outcomes were evaluated by the imme-
diate hemostatic results, presence of rebleeding, and dura-
tion of hemostasis. Patients in the reconstructive group
underwent follow-up contrast-enhanced computed to-
mography (CT), CT angiography, ultrasonography, or
conventional angiography within the first month and then
every 2 to 4months so that patency of the stent grafts could
be assessed. Patients in the deconstructive group under-
went regular clinical outpatient department follow-up ev-
ery 6 months. If rebleeding occurred, emergency angiog-
raphy and interventional management were performed.
Follow-up lasted a median of 4 months (mean, 9.34 
11.42 [range, 0.1-37] months).
Statistical analysis. We analyzed the technical out-
comes and hemostatic outcomes of our patients, including
technical success, initial and delayed complications, patency
of the stent grafts in the reconstructive group, immediate
hemostasis, presence of rebleeding, and duration of hemo-
stasis after initial intervention by using the t test, 2 test, or
Fisher exact test, when appropriate. Age, sex, type of CBS,
local wound complication, angiographic severity, location
of the pathologic lesion, and type of endovascular manage-
ment were examined as predictors for outcome analysis by
using Cox regression analysis. Clinical severity of CBS was
correlated with angiographic severity by using the Fisher
exact test. For all analyses, P  .05 was considered statisti-
cally significant.
RESULTS
Baseline characteristics. Table I summarizes the
baseline characteristics of all patients. Adjustments for sex,
age, clinical diagnosis, local wound complication, clinical
and angiographic severity, and location of pathologic lesion
(including lesions in ICA and other than ICA) did not
affect the results.
Clinical and angiographic classification. The corre-
lation between clinical and angiographic severity is shown
in Fig 3. Pseudoaneurysms (grade 2) were the most com-
mon angiographic findings and were present in all clinical
groups. Active extravasation (grade 3) was only noted in
patients with acute CBS. All 11 patients with acute CBS
had advanced (grade 2 and 3) carotid disruption on angio-
gram (100%). Clinical severity correlated well with the
angiographic severity (P  .002).
Fig 1. A, Left carotid angiogram in patient 10 of the rec
carotid artery (grade 0, arrow).B,Contrast-enhanced axi
sinus tract (arrowheads) close to the left common caroti
multiplanar reformatted images) of the left carotid arter
months later, obvious distal marginal stenosis was noted
(arrows) surrounding the stent grafts caused “floating” of leftTechnical outcome. Endovascular management was
successfully accomplished in all 24 patients during the
initial procedures (Tables II, III, and IV). Four initial
complications (36.4%) occurred in the 11 patients in the
reconstructive group, including acute thromboembolism
in three patients, and dissection and a type 3 endoleak in
one patient. Only one of these four initial complications
was symptomatic (patient 3). A delayed complication in the
reconstructive group included septic thrombosis of the
stent graft with multiple brain abscesses in one patients
(9.1%).
Of the 13 patients in the deconstructive group, an
initial complication was an acute infarction in the territory
of MCA in one patient (7.7%). One patient (7.7%) also
presented with brain abscess as a delayed complication after
deconstructive management. An initial complication was
noted in one of six patients (16.7%) in the deconstructive
group with pathologic lesions located in the CA other than
ICA and no patients with a lesion located in the ICA (P 
.462). Delayed complications were found in two of seven
patients (28.6%) with pathologic lesions located in ICA and
one of six patients (16.7%) with lesions located in the CA
other than ICA (P  .612).
Follow-up imaging performed 3 months demon-
strated that nine patients (except for patients 1 and 2) in the
reconstructive group had patent stent grafts. Varying de-
grees of distal marginal stenosis were noted in five of the six
patients (83.3%) in the reconstructive management group
after a 3-month follow-up. One (patient 9) of these five
patients was successfully treated with angioplasty and stent-
ing 3 months after the initial intervention. Of the six
patients who were followed up longer than 3 months, three
(50%) had occluded stent grafts, and two of these (patients
6 and 7) were asymptomatic. Patient 4 presented with
septic thrombosis and multiple brain abscesses. The mean
duration of stent graft patency was 3.0  2.6 months.
Hemostatic outcome and survival analysis.
Immediate hemostasis was achieved in all patients in both
groups after the interventional procedures (Tables II, III,
and IV). Seven episodes of rebleeding were noted in five of
the 11 patients (45%) in the reconstructive group. All of
them had acute CBS, and rebleeding resulted in death in
two of these patients. The other three patients, in whom
five episodes of rebleeding from the same diseased CAs
occurred, were successfully managed by reintervention.
The duration of hemostasis after initial reconstructive man-
agement was a mean of 4.0  8.1 months (range, 0.02-9
months). Three of the 13 patients (23.1%) had rebleeding
3 months after initial deconstructive management. All who
had rebleeding had undergone proximal occlusion (3 of 5
uctive group showed only slight stenosis in the common
puted tomography (CT) of the neck revealed a necrotic
ry (arrow). C, Reconstructive CT angiography (curved
onth later showed patency of the stent grafts. D, Four
wheads). Large area of soft tissue necrosis and ulcerationonstr
al com
d arte
y 1 m
(arrocarotid artery (long arrows).
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initial deconstructive management was 8.5 10.1 months
(range, 0.5-37 months).
Themean survival of patients was 11.9 4.8months in
the reconstructive group and 12.2  4.1 months in the
deconstructive group. No predictors for survival were
found using Cox regression analysis.
Statistical analysis. There were no significant differ-
ences in initial and delayed complications, rebleeding rate,
duration of hemostasis, and survival time between the
reconstructive and deconstructive groups (Table IV). Pa-
tients in the deconstructive group who had undergone
cross occlusion had a lower rebleeding rate than those who
underwent proximal occlusion (0% vs 60%, P  .035).
The rebleeding rates of hemostatic outcome were cor-
related with clinical severity (Table V). Patients with acute
CBS had a higher bleeding rate (P .008). There were no
statistically significant differences in technical outcome and
duration of hemostasis with clinical severity.
DISCUSSION
Carotid blowout syndrome in patients with head and
neck cancers often results in catastrophic hemorrhage. Al-
though deconstructive endovascular therapy has improved
patient outcomes, it carries a risk of cerebral ischemia.1,6
Reconstructive endovascular therapy for CBS with stent
grafts has been proposed; however, recent reports have
shown unfavorable durable hemostasis and long-term out-
comes.5,7 In our previous study, we treated eight CBS
patients with high risk of carotid occlusion with stent
Fig 2. A, Right carotid angiograms in patient 8 of the decon-
structive group showed a ruptured internal carotid artery with
active extravasation (grade 3, arrows). B, Cross occlusion was
performed with deployment of two balloons distal and proximal to
the pathologic lesions (arrows). A mixture of liquid adhesives was
injected in the internal carotid artery between the 2 balloons
Fig 3. Graph shows correlation of clinical severity (groups: acute,
impending, and threatened) with angiographic severity (grades 0,
1, 2, and 3).(arrowheads).
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their poor technical outcomes (no stent graft patency after
3-month follow-up) and poor hemostatic outcomes (50%
rebleeding rate). We therefore ended the application of
stent grafts to treat these cancer patients with CBS in
emergency or temporary practice.
Recently, however, we found distal marginal stenosis
was a common cause of stent graft occlusion and inade-
quate coverage of the ongoing pathologic lesion by the
Table II. Summary of reconstructive management of 11 p
Patient
Technical outcome
Initial management:
stent graft (mm)a
Complications:
initial/delayed
(time)
Follo
stent
1 8  50 Acute
asymptomatic
ICA thrombosis,
occlusion/none
Not a
2 8  30 None/none Not a
3 8  50c Embolic infarct,
treated with
thrombolytic
therapy/none
1 mo:
4 8  50c None/brain abscess
(4 mo)
2 mo:
4 m
thro
5 9  70 None/none 0.5 m
6 7  30 Transient
asymptomatic
in-stent
thrombosis/none
3 mo:
6 m
asym
thro
7 8  50 None/none 3 mo:
3.7
sten
6 m
asym
thro
8 9  70 None/none 0.5 m
9 8  50c Asymptomatic CA
dissection treated
with 7  40
Wallstente/none
4 mo:
trea
7 
Wal
mo:
10 8  50, 9  70c None/none 4 mo:
11 8  50, 9  70c None/none 4 mo:
CA, Carotid artery; ICA, internal carotid artery; UGI, upper gastrointestin
Initial technical success and immediate hemostasis were achieved in all patie
aWallgraft: Boston Scientific Corporation, Natick, Mass.
bTime of follow-up.
cPlus fiber coils in the external carotid artery.
dDistal marginal stenosis.
eCarotid Wallstent: Boston Scientific Corporation.stent graft was a cause of the rebleeding. With technicalimprovement to manage these complications, we have seen
better recent outcomes than the previous work. Therefore,
we designed this study to test if endovascular reconstruc-
tion by using self-expandable stent grafts has worse techni-
cal and hemostatic outcomes than those of endovascular
deconstruction by using balloons, coils, or acrylic adhesive
to manage CBS in patients with head and neck cancers. We
found the difference of the outcomes between these 2
methods was insignificant. The outcomes were significantly
ts with carotid blowout syndrome
Hemostatic outcome
for
ncy
Time of rebleeding/
reintervention
Outcome/timeb
(cause of death)
ble 0.6 mo, disease
progression/none
Died/0.6 mo (rebleeding)
ble 0.1 mo, inadequate
coverage of the lesion/
none
Died/0.1 mo (rebleeding)
cy None Died/2 mo (disease
progression)
cy;
tic
sis
None Alive/28 mo
ency None Died/1.5 mo (disease
progression,
mediastinitis)
sisd;
atic
sis
0.5 mo, disease
progression/9  50
Wallgraft
Died/36 mo (lung
metastasis)
cy;
;
atic
sis
2 mo, disease
progression/8  50
Wallgraft; 3 mo/direct
percutaneous puncture
of ECA for
embolization
Alive/27 mo
ency None Died/1 mo (lung
metastasis)
sisd
ith
e; 9
ncy
0.02 mo, type 3 endoleak
by the Wallstente/9 
70 Wallgraft, direct
percutaneous puncture
for embolization;
9 mo, recurrent type
3 endoleak/10 
70-mm Wallgraft
Died/9.1 mo (transfusion
complication, sepsis)
sisd None Died/4.5 mo (sepsis,
disease progression)
sisd None Died/4 mo (UGI
bleeding, transfusion
complication)atien
w-up
pate
pplica
pplica
paten
paten
o: sep
mbo
o: pat
steno
o:
ptom
mbo
paten
mo:
osisd
o:
ptom
mbo
o: pat
steno
ted w
50
lstent
pate
steno
steno
al.
nts.influenced by the clinical severity of CBS of our patients.
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to justify the occlusion of a patent CA or predict whether it
will cause a neurologic deficit. Autogenous venous or arte-
rial reconstruction has been proposed in the treatment of
patients with advanced head and neck cancers with invasion
to the carotid system.15 This autogenous tissue reconstruc-
tion is valuable in avoiding cerebral ischemic insult when
complete resection of the tumor and CA is needed. Com-
pared with surgical autogenous tissue reconstruction, the
merits of endovascular stent graft reconstruction include:
1. Less invasiveness because the endovascular reconstruc-
Table III. Summary of deconstructive management of 13
Patient
Technical outcome
Initial management:
permanent carotid occlusion
(method)
Complications:
initial/delayed (time
1 NBCA w/prox balloon (B) None/none
2 NBCA w/prox balloon (B) None/none
3 NBCA w/prox balloon (B) None/none
4 2 balloons (B) None/none
5 2 balloons (A) None/none
6 Coils, NBCA w/prox
balloon (B)
None/none
7 2 balloons (A) None/none
8 Distal balloon, NBCA w/
prox balloon (B)
None/none
9 2 balloons (A) Embolic infarct/non
10 2 balloons (A) None/brain abscess
(0.5 mo)
11 NBCA w/prox balloon (B) None/none
12 2 balloons (A) None/none
13 10 fiber coils w/prox
balloon (B)
None/none
(A), Proximal occlusion; (B), cross occlusion; NBCA, N-Butyl-2-cyanoacry
Initial technical success and immediate hemostasis were achieved in all patie
aTime of follow-up.
Table IV. Analysis of technical and hemostatic outcomes
of reconstructive and deconstructive endovascular
management
Outcome
Reconstructive
(n  11)
Deconstructive
(n  13) P
Technical outcome,
No. (%)
Initial complication 4 (36.4) 1 (7.7) .142
Delayed complication 1 (9.1) 1 (7.7) .99
Hemostatic outcome
Rebleeding, No. (%) 5 (45.5) 3 (23.1) .659
Hemostasis duration,
mean  SD mo 4.0  8.1 8.5  10.1 .249
Survival time, mean 
SD mo 11.9  4.8 12.2  4.1 .547tion can be performed under local anesthesia and doesnot need any tissue harvesting. It also needs no explo-
ration in the soft tissue of the irradiated neck region.
2. No temporary interruption of CA flow because endo-
vascular reconstruction does not need temporary clamp-
ing of the CA for vascular replacement and thus may
reduce the risk of cerebral ischemia. This is especially
important when the patients of CBS present with pro-
fuse bleeding and hypovolemic status.
3. Suitable for palliative care. For selected patients with
advanced head and neck cancers with CBS, endovascu-
lar stent graft reconstruction is good for achieving im-
ents with carotid blowout syndrome
Hemostatic outcome
Time of rebleeding
Outcome/timea
(cause of death)
None Died/10 mo (multiple metastasis,
sepsis)
None Alive/37 mo
None Alive/4 mo
None Died/0.5 mo (radiation myelopathy,
sepsis)
None Died/2 mo (recurrent tumor, sepsis)
None Died/5 mo (brain metastasis, sepsis)
3 mo (2 mo: drop off
the balloon by
débridement )
Died/3 mo (disease progression,
rebleeding)
None Died/18 mo (sepsis, disease
progression)
3 mo Died/3 mo (rebleeding)
3 mo Died/3 mo (recurrent tumor
w/rebleeding)
None Died/1 mo (disease progression,
sepsis)
None Alive/14 mo
None Alive/10 mo
Histoacryl, Braun, Germany).
Table V. Analysis of clinical severity of carotid blowout
syndrome and endovascular outcomes
Variable
Acute
(n 11)
Impending
Threatened
(n  13) P
Angiographic grade, No. (%)
0 and 1 0 (0) 8 (61.5) .002
2 and 3 11 (100) 5 (38.5)
Technical outcome, No. (%)
Initial complications 4 (36.3) 1 (7.7) .142
Delayed complications 1 (9.1) 1 (7.7) .99
Hemostatic outcome
Rebleeding, No. (%) 7 (63.6) 1 (7.1) .008
Hemostasis duration,
mean  SD mo 3.9  5.5 8.6  11.4 .231pati
)
e
late (
nts.mediate and temporary hemostasis.11
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groups: acute, impending and threatened.1,7 This simple
clinical classification correlated well with angiographic se-
verity in our study. We favor making this clinical classifica-
tion as a guide for management of CBS. Typically, patients
with acute CBS were diagnosed by clinical and angio-
graphic findings; however, patients with threatened or im-
pending CBS can present with subtle or no angiographic
abnormalities (grades 0 and 1).
One of the causes of CBS in a CA without obvious
angiographic abnormalities was that the angiogram was ob-
tained in the earliest stage of CBS. The vulnerable CA was
intact but had been surrounded by diseased soft tissue such as
recurrent tumor or irradiation necrosis. Correlating other
image modalities such as CT or magnetic resonance imaging
of the head and neck region can help in achieving early
diagnosis (Fig 1). Another cause is that the subtle pathologic
lesions were not shown on routine biplanar angiograms. We
suggest obtaining multiple view angiograms or CT angio-
grams to aid in the evaluation of patients with CBS without
obvious angiographic abnormalities (Fig 1).16,17
Cerebral ischemic insult is a well-known initial compli-
cation of deconstructive management of CBS.1,18 Recon-
structive management, however, also carries the risk of
thromboembolism and procedurally related complications
such as vascular dissection.11,13 These complications may
be caused by inadequate antithrombotic medication treat-
ment of the patients or product characteristics of the de-
vices. The development of a new design of self-expandable
stent graft with a less thrombogenic surface, higher flexi-
bility, and lower profile is indicated to improve technical
safety of reconstructive endovascular management.
The mean duration of stent graft patency in this study
was 3.0 2.6 months. This unfavorable long-term patency
is a limitation of the reconstructive method as a permanent
way to manage patients with head and neck cancers and
CBS. The causes of poor long-term stent graft patency
were:
1. Appropriate antithrombotic medications are usually not
effective in cases of acute or advanced clinical status, and
early management for patients in a stable condition can
improve the outcome with adequate antithrombotic
regimens.
2. The thrombogenic character of stent grafts needs more
adequate antithrombotic medications. Our patients
with threatened CBS were given clopidogrel and aspirin
only for 1 day before intervention. If we could diagnose
the disease at its very early stage, it potentially might do
better if the drugs were given for at least 3 days before
the standard carotid angioplasty and stenting.
3. The deployment of stent grafts in a contaminated field
in patients with head and neck cancers may result in
persistent infection and ultimately cause septic throm-
bosis of the CA.19 We recommend prophylactic antibi-
otics before and after the intervention.
4. Distal marginal stenosis was a common cause of recur-
rent vascular narrowing or occlusion after stent graftdeployment.20 It may be caused by vascular remodeling
due to the high radial force of the self-expandable stent
grafts.21,22 The smaller diameter of the CA distal to the
stent graft may suffer from stronger pressure than its
proximal side and thus cause distal marginal stenosis
(Fig 1). Because it showed rapid temporal change, close
follow-up and early management are needed to improve
the outcomes in patients with stents.
These technical improvements may help stent grafting to
be a good alternative method for patients at high risk for
carotid occlusion.
Both endovascular methods were good at achieving
immediate hemostasis. Although not statistically signifi-
cant, deconstructive management provided better hemo-
static results than reconstructive management (Table IV).
Reconstructive management with stent grafts covered only
a segment of the affected CA. The pathologic field in the
patients with head and neck cancers can show dynamic
changes as a result of complex factors such as tumor recur-
rence, wound infection, or radiation necrosis. This ongoing
pathologic process may progress over the initially treated area
(Fig 1). We suggest assessing the extent of the pathologic
lesion on CT and the field of previous irradiation before stent
graft placement is planned. A long, self-expandable stent graft
can fully cover the pathologic field, especially given the
continuous shortening of the self-expanding stent graft as it
dilates progressively.
This ongoing pathologic process with reconstitution of
collateral vessels or recanalization of the thrombosed CAs
may also explain the rebleeding in patients in the decon-
structive group who underwent proximal occlusion.23 We
suggest performing deconstructive endovascular therapy
with cross occlusion for these cancer patients with CBS to
enhance durable hemostasis if they have no risk of perma-
nent carotid occlusion (Fig 2). Cross occlusion is favored as
a permanent deconstructive method to treat CBS because
of its low rebleeding rate. Reconstructive endovascular
therapy with a stent graft is reserved for patients who are
not suitable for the deconstructive method.
For all patients, clinical severity is the significant factor
affecting the hemostatic outcome of endovascular manage-
ment (Table V). Rebleeding occurred more commonly in
patients with acute CBS than in those in the impending and
threatened group. Poor hemostatic results in patients with
acute status included patients with acute CBS who also had
a more extensive and complete CA injury or soft tissue
injury, or both, than those with impending and threatened
CBS and the critical clinical status, and thus poor cooper-
ation of these patients could cause technical difficulty such
as the precise positioning of the stent graft deployment, as
in patient 2 in the reconstructive group; in addition, pa-
tients with acute CBS have complications that may be due
to inadequate antithrombotic medication or massive trans-
fusion. We suggest making an early diagnostic and treat-
ment plan, such as CT or angiography with an occlusion
test, for patients with head and neck cancers if signs sug-
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stable clinical condition may also improve the outcomes.
A limitation of this study was the small number of
patients studied, many of whom had a short survival time,
which hindered long-term follow-up. Diverse disease
stages and previous treatment of our patients also made
statistical analysis difficult. Comparing the two techniques
is also difficult because patients who received stent grafts
are often those who cannot tolerate carotid occlusion or in
whom test occlusion is precluded by their clinical status.
A lack of experiencewith antithromboticmedications and
prophylactic antibiotics might also have affected outcomes of
patients in the reconstructive group. Further research with
improved prophylactic medications and associated other im-
age modalities such as CT or CT angiography for early diag-
nosis is invaluable to improve the outcomes.
CONCLUSION
We found no significant differences in the technical and
hemostatic outcomes of reconstructive and deconstructive
endovascular management. Clinical severity is a significant
factor affecting hemostatic outcome of endovascular man-
agement: patients with acute CBS were associated with a
higher rebleeding rate than those with impending and
threatened CBS. We suggest correlation of clinical findings
and other image modalities such as CT to help in early
diagnosis of CBS if angiographic abnormalities are subtle.
We also suggest early endovascular management for pa-
tients with CBS. Deconstructive endovascular manage-
ment with cross occlusion can be a treatment for durable
hemostasis.
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